구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Alemtuzumab |
Overview Company | Miltenyi Biomedicine GmbH |
Overview Modality | ANTIBODY |
Overview Target | Fanconi Anemia |
Overview Indication | Leukemia; Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeting CD52, a glycosylphosphatidylinositol-anchored surface antigen |
MoA Biomarker | biomarkers of axonal damage were observed |
PK/PD Half-life | 11 h |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Urinary tract infections, urosepsis, and multiple sclerosis disease modifying therapies: a disproportionality analysis of the FDA Adverse Event Reporting System.. Infection-related complications, including urinary tract infections (UTIs) and urosepsis, account for a significant proportion of morbidity and mortality in patients with advanced multiple sclerosis (MS). However, the role of specific di… |
Toxicology CRS | Reported |
Clinical Safety signal | Urinary tract infections, urosepsis, and multiple sclerosis disease modifying therapies: a disproportionality analysis of the FDA Adverse Event Reporting System.. Infection-related complications, including urinary tract infections (UTIs) and urosepsis, account for a significant proportion of morbidity and mortality in patients with advanced multiple sclerosis (MS). However, the role of specific di… |
Clinical Reported PFS | NA |
Clinical Reported OS | 16 |
Clinical Result source | ClinicalTrials.gov NCT02059239 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02059239 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Alemtuzumab |
Overview Company | Miltenyi Biomedicine GmbH |
Overview Modality | ANTIBODY |
Overview Target | Fanconi Anemia |
Overview Indication | Leukemia; Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeting CD52, a glycosylphosphatidylinositol-anchored surface antigen |
MoA Biomarker | biomarkers of axonal damage were observed |
PK/PD Half-life | 11 h |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Urinary tract infections, urosepsis, and multiple sclerosis disease modifying therapies: a disproportionality analysis of the FDA Adverse Event Reporting System.. Infection-related complications, including urinary tract infections (UTIs) and urosepsis, account for a significant proportion of morbidity and mortality in patients with advanced multiple sclerosis (MS). However, the role of specific di… |
Toxicology CRS | Reported |
Clinical Safety signal | Urinary tract infections, urosepsis, and multiple sclerosis disease modifying therapies: a disproportionality analysis of the FDA Adverse Event Reporting System.. Infection-related complications, including urinary tract infections (UTIs) and urosepsis, account for a significant proportion of morbidity and mortality in patients with advanced multiple sclerosis (MS). However, the role of specific di… |
Clinical Reported PFS | NA |
Clinical Reported OS | 16 |
Clinical Result source | ClinicalTrials.gov NCT02059239 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02059239 |
추천 비교
추천 비교